Table 1 Demographics of amyloid PET GWAS participants at the time of scanning. This table summarizes basic demographic information of participants included in the analysis. For each cohort, we report number of participants, percentage of females and males, mean age of the participants and standard deviation (SD) in the age, percentage of APOE ε4-carriers (APOE ε4 + participants), and percentage of cases and control participants, where available. To normalize amyloid PET endophenotype across different cohorts, we converted different amyloid imaging measures (e.g., Centiloid, PiB, and AV45) into log-normalized z-score using “scale” function in base R. Phenotype from each cohort was normalized individually to account for within cohort variation. Abbreviations: PET, positron emission tomography; sd, standard deviation; Knight-ADRC, Knight Alzheimer’s Disease Research Center; ADNI, Alzheimer's Disease Neuroimaging Initiative; DIAN, the Dominantly Inherited Alzheimer Network; A4, Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease; ADNI-DOD, ADNI Department of Defense studies; AIBL, Australian Imaging, Biomarkers and Lifestyle; HABS, The Harvard Aging Brain Study; UPitt, University of Pittsburgh; MCSA, Mayo Clinic Study of Aging; WRAP, Wisconsin Registry for Alzheimer's Prevention; BACS, Berkeley Aging Cohort study; SUVR, standardize uptake value ratios; FBP, Florbetapir; PIB, Pittsburgh Compound-B; FMT, Flutemetamol
From: Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease
Variables | Total | A4 | ADNI | AIBL | ADNI-DOD | DIAN | HABS | Knight-ADRC | UPitt | Korean | Memento | MCSA | WRAP | BACS | MISSION-AD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tracer | – | SUVR | FBP | FBP/PIB/FMT | AV45 | PIB | PIB | PIB/AV45 | PIB | AV45 | FBP/FMT | PIB | PIB | PIB | FBP/FBB/ FMT |
Total | 13,409 | 3,180 | 1,134 | 1,214 | 169 | 209 | 258 | 1,048 | 345 | 996 | 630 | 1712 | 78 | 173 | 2,263 |
Female (%) | 48.52 | 60.09 | 47 | 54.04 | 0.59 | 52.63 | 59.3 | 54.77 | 45.8 | 56.9 | 59.25 | 46.3 | 35 | 59 | 48.6 |
Male (%) | 51.48 | 39.91 | 53 | 45.96 | 99.41 | 47.37 | 40.7 | 45.23 | 54.2 | 43.1 | 40.75 | 53.7 | 65 | 41 | 51.4 |
Age (mean) | 69.63 | 71.30 | 73.73 | 72.65 | 69.08 | 36.60 | 73.99 | 70.74 | 78.39 | 70.15 | 71.55 | 73.4 | 67 | 74.49 | 71.8 |
Age (sd) | 7.65 | 4.73 | 7.62 | 6.62 | 4.67 | 10.86 | 6.1 | 9.01 | 9.91 | 8.72 | 8.15 | 10.6 | 6.02 | 6.30 | 7.8 |
APOE4 + (%) | 35.06 | 36.04 | 43.39 | 35.01 | 26.63 | 28.71 | 29.84 | 41.13 | 32.46 | 41.7 | 28.65 | 28.6 | 42 | 28 | 48.7 |
Cases (%) | 35.17 | 0.06 | 61.55 | 7.5 | 32.54 | 45.01 | 27.13 | 16.98 | 12.17 | 69.8 | 100 | 15.7 | 5 | 0 | 99 |
Controls (%) | 60.69 | 99.94 | 32.36 | 79.74 | 67.46 | 38.28 | 72.87 | 61.83 | 87.83 | 30.2 | 0 | 84.1 | 95 | 100 | 0 |